Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1580-1586

  Pillet, Sylvie ^a,b   Jarlot, Camille ^b   Courault, Mathilde ^a   Del Tedesco, Emilie ^b   Chardon, Renaud ^a   Saint Sardos, Pierre ^a,b   Presles, Emilie ^c   Phelip, Jean Marc ^b   Berthelot, Philippe ^a   Pozzetto, Bruno ^a,b   Roblin, Xavier ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c INSERM   (France)

Author keywords

anti TNF mabs; cytomegalovirus reactivation; flare up of ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; VIRUS DNA; ANTIVIRUS AGENT; GASTROINTESTINAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COLON; COLON BIOPSY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; MONOTHERAPY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIRUS LOAD; VIRUS REACTIVATION; BIOPSY; COLITIS, ULCERATIVE; COLONOSCOPY; COMPLICATION; CYTOMEGALOVIRUS INFECTIONS; GENETICS; MIDDLE AGED; PATHOLOGY; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTIVIRAL AGENTS; BIOPSY; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS ACTIVATION;

EID: 84932146855     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000412     Document Type: Article

References (51)

1. Sinzger C, Grefte A, Plachter B, et al. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol. 1995; 76:741-750.
2. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857-2865.
3. Pillet S, Pozzetto B, Jarlot C, et al. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis. 2012;44: 541-548.
4. Roblin X, Pillet S, Berthelot P, et al. Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease. Inflamm Bowel Dis. 2012;18:E1396-E1397.
5. Domenech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14:1373-1379.
6. Kambham N, Vij R, Cartwright CA, et al. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28:365-373.
7. Barahona-Garrido J, Martinez-Benitez B, Espinosa-Cardenas E, et al. Cytomegalovirus infection in patients who required colectomy for toxic megacolon or severe steroid-refractory ulcerative colitis. Dig Dis Sci. 2010;55:867-868.
8. Kim JJ, Simpson N, Klipfel N, et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55:1059-1065.
9. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001-2008.
10. Matsumoto S, Yoshida Y. What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis?. Eur J Gastroenterol Hepatol. 2014;26:282-287.
11. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8: 443-468.
12. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012; 380:1606-1619.
13. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
14. Rizzo G, Pugliese D, Armuzzi A, et al. Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?. World J Gastroenterol. 2014;20:4839-4845.
15. Monterubbianesi R, Aratari A, Armuzzi A, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis. 2014;8:852-858.
16. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380: 1909-1915.
17. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010; 105:2617-2625.
18. Freeman HJ. Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag. 2013;9: 451-456.
19. Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19:1700-1709.
20. Sandborn WJ, Colombel J-F, DHaens G, et al. One-year maintenance outcomes among patients with moderately-To-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37:204-213.
21. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-Tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34.
22. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-Tumour necrosis factor therapy. Eur J Gastroenterol Hepatol. 2002;14:1393-1395.
23. Haerter G, Manfras BJ, de Jong-Hesse Y, et al. Cytomegalovirus retinitis in a patient treated with anti-Tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis. 2004;39:e88-e94.
24. Mizuta M, Schuster MG. Cytomegalovirus hepatitis associated with use of anti-Tumor necrosis factor-Alpha antibody. Clin Infect Dis. 2005;40: 1071-1072.
25. Kohara MM, Blum RN. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-Tumor necrosis factor-Alpha antibody. Clin Infect Dis. 2006;42:733-734.
26. McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:131-137.
27. Ali T, Kaitha S, Mahmood S, et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79-99.
28. Nakase H, Yamamoto S, Matsuura M, et al. Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. Aliment Pharmacol Ther. 2010;32:510-511.
29. Yoshino T, Nakase H, Matsuura M. Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis. Aliment Pharmacol Ther. 2012;36: 811-812.
30. Park SH, Yang S-K, Hong S-M, et al. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci. 2013;58:3592-3599.
31. Yamada S, Yoshino T, Matsuura M, et al. Long-Term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol. 2014;14:80.
32. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
33. Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-Time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007;13:1516-1521.
34. You DM, Johnson MD. Cytomegalovirus infection and the gastrointestinal tract. Curr Gastroenterol Rep. 2012;14:334-342.
35. Kim JW, Boo S-J, Ye BD, et al. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2014;8:693-701.
36. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568-2576.
37. Minami M, Ohta M, Ohkura T, et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol. 2007;13:754-760.
38. Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis. 2007; 13:896-902.
39. Torre-Cisneros J, Del Castillo M, Caston JJ, et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatoly (Oxford). 2005;44:1132-1135.
40. DHaens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
41. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBDsubgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30:210-226.
42. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation. 1994; 58:675-680.
43. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-Alpha specifically induce formation of cytomegaloviruspermissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest. 1997;100:3154-3163.
44. Simon CO, Seckert CK, Dreis D, et al. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol. 2005;79:326-340.
45. Matsumura K, Nakase H, Kosugi I, et al. Establishment of a novel mouse model of ulcerative colitis with concomitant cytomegalovirus infection: in vivo identification of cytomegalovirus persistent infected cells. Inflamm Bowel Dis. 2013;19:1951-1963.
46. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343:268-269.
47. Asadullah K, Prosch S, Audring H, et al. A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol. 1999;141:94-102.
48. Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res. 2014;12:5-11.
49. DOvidio V, Vernia P, Gentile G, et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol. 2008;43:180-183.
50. Criscuoli V, Mocciaro F, Orlando A, et al. Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis. Inflamm Bowel Dis. 2009;15:810-811.
51. Nakase H, Chiba T. TNF-Alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Inflam Bowel Dis. 2010;16:550-551.